CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Opiant Pharmaceuticals Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Opiant Pharmaceuticals Inc
233 Wilshire Blvd, Suite 400
Phone: (310) 598-5410p:310 598-5410 SANTA MONICA, CA  90401  United States Fax: (302) 636-5454f:302 636-5454

This company was Merged or Acquired on 3/2/2023.
This company ceased filing statements with the SEC on 3/13/2023.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company

Business Summary
Opiant Pharmaceuticals, Inc., is a specialty pharmaceutical company developing medicines for addictions and drug overdose. The Company has developed NARCAN (naloxone hydrochloride) Nasal Spray, a treatment to reverse opioid overdose. Its lead development product include OPNT003. The Company’s pipeline includes medicines in development for Opioid Overdose Reversal (OOR), Alcohol Use Disorder (AUD), Opioid Use Disorder (OUD), and Acute Cannabinoid Overdose (ACO). The Company also is focused on other treatment opportunities within the addiction and drug overdose field.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
9/30/202212/31/2021YesYes---

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chief Executive Officer, Director RogerCrystal 45 9/23/2009 9/23/2009
Chief Financial Officer David D.O'Toole 63 9/1/2017 9/1/2017
Chief Scientific Officer PhilSkolnick 75 2/1/2017 2/1/2017
5 additional Officers and Directors records available in full report.

Business Names
Business Name
Lightlake Therapeutics Inc.
Lightlake Therapeutics(NDA)
Madrona Ventures Inc
4 additional Business Names available in full report.

General Information
Number of Employees: 37 (As of 12/31/2021)
Outstanding Shares: 5,268,677 (As of 1/4/2023)
Shareholders: 35
Stock Exchange: NASD
Federal Tax Id: 464744124
Fax Number: (302) 636-5454


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, July 3, 2024